---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-031170"
form_type: "8-K"
ticker: "GLSI"
cik: "0001799788"
company_name: "Greenwich LifeSciences, Inc."
filed_at: "2021-12-13T23:59:59+00:00"
generated_at: "2026-06-28T01:47:19.639834+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Greenwich LifeSciences reports 5-year GP2 Phase IIb data: baseline immune response predicts recurrence

## Summary
- 22.8% of 145 patients had positive baseline DTH response to GP2; 24.2% recurrence rate over 5 years (median 99 days).
- Patients without baseline response had 12.5% recurrence rate with median time to recurrence of 438 days.
- HER2+ patients completing GP2 primary series showed 100% DFS vs 89.4% for placebo (p=0.0338) over 5 years.
- GP2 treatment was well tolerated with no serious adverse events attributed to GLSI-100.
- Company plans Phase III trial in 2022 and exploration of GP2-specific CAR-T cell candidates.

## SEC filing metadata
- accession: 0001493152-21-031170
- form_type: 8-K
- ticker: GLSI
- cik: 0001799788
- company_name: Greenwich LifeSciences, Inc.
- filed_at: 2021-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799788/000149315221031170/0001493152-21-031170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799788/000149315221031170/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-031170
- JSON: https://secwatch.observer/filing/0001493152-21-031170.json
- Plain text: https://secwatch.observer/filing/0001493152-21-031170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.